FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2734929604> ?p ?o ?g. }

• W2734929604 endingPage "e361" @default.
• W2734929604 startingPage "e350" @default.
• W2734929604 abstract "Background GP2013 is a rituximab biosimilar developed to stringent development guidelines, including non-clinical and preclinical investigations and clinical trials in rheumatoid arthritis and follicular lymphoma. We aimed to compare the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of GP2013 plus cyclophosphamide, vincristine, and prednisone (GP2013-CVP) with rituximab-CVP (R-CVP) in patients with follicular lymphoma. Methods In this phase 3, multinational, double-blind, randomised, controlled trial, adults (aged 18 years or older) with previously untreated, advanced stage (Ann Arbor stage III or IV) follicular lymphoma of WHO histological grades 1, 2, or 3a were randomly assigned (1:1) using interactive response technology to eight cycles of GP2013-CVP or R-CVP (combination phase), followed by monotherapy maintenance in responders for a 2-year period. Randomisation was stratified by Follicular Lymphoma International Prognostic Index risk group and geographic region. The primary endpoint was comparability in overall response, with equivalence concluded if the entire 95% CI was within a margin of −12% to 12%. The primary endpoint was analysed using the per-protocol set, which included all patients who received at least one (partial or complete) dose of investigational treatment and who did not have any major protocol deviations. The trial is registered with ClinicalTrials.gov, number NCT01419665, and is ongoing. Findings Between Dec 1, 2011, and Jan 15, 2015, 858 patients were screened for eligibility. 314 patients were randomly assigned to GP2013, of whom 312 were given GP2013, and 315 were assigned to reference rituximab. Median follow-up was 11·6 months (IQR 5·8–18·2) for the primary analysis. The primary endpoint, equivalence of overall response, was met (271 [87%] of 311 patients with GP2013 and 274 [88%] of 313 patients with reference rituximab achieved an overall response; difference −0·40% [95% CI −5·94 to 5·14]). Occurrence of adverse events and serious adverse events was similar between the treatment groups (289 [93%] of 312 patients in the GP2013-CVP group had an adverse event and 71 [23%] of 312 patients had a serious adverse event; 288 [91%] of 315 patients in the R-CVP group had an adverse event and 63 [20%] had a serious adverse event). The most common adverse event was neutropenia (80 [26%] of 312 patients in the GP2013-CVP group and 93 [30%] of 315 patients in the R-CVP group in the combination phase and 23 [10%] of 231 patients in the GP2013-CVP group and 13 [6%] of 231 patients in the R-CVP group in the maintenance phase). The most common grade 3 or 4 adverse event during the combination and maintenance phase was neutropenia (55 [18%] of 312 patients in the GP2013-CVP group and 65 [21%] of 315 patients in the R-CVP group in the combination phase and 17 [7%] of 231 patients in the GP2013-CVP group and nine [4%] of 231 patients in the R-CVP group in the maintenance phase). The occurrence of anti-drug antibodies was similar in the treatment groups (five [2%] of 268 patients in the GP2013-CVP; three [1%] in the R-CVP group). Interpretation Our results show that GP2013 represents a viable rituximab biosimilar candidate for patients with previously untreated advanced follicular lymphoma. The introduction of biosimilars provides additional therapeutic options with potential to increase access to effective and life-saving biological therapies such as rituximab. Funding Hexal." @default.
• W2734929604 created "2017-07-21" @default.
• W2734929604 creator A5003727895 @default.
• W2734929604 creator A5003883532 @default.
• W2734929604 creator A5015424908 @default.
• W2734929604 creator A5017916035 @default.
• W2734929604 creator A5021098298 @default.
• W2734929604 creator A5027127504 @default.
• W2734929604 creator A5033728782 @default.
• W2734929604 creator A5042926407 @default.
• W2734929604 creator A5043670888 @default.
• W2734929604 creator A5046659441 @default.
• W2734929604 creator A5049279419 @default.
• W2734929604 creator A5059428070 @default.
• W2734929604 creator A5060558357 @default.
• W2734929604 creator A5065418651 @default.
• W2734929604 creator A5076337256 @default.
• W2734929604 creator A5087764727 @default.
• W2734929604 date "2017-08-01" @default.
• W2734929604 modified "2023-10-16" @default.
• W2734929604 title "Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study" @default.
• W2734929604 cites W1912693401 @default.
• W2734929604 cites W2048354162 @default.
• W2734929604 cites W2049274660 @default.
• W2734929604 cites W2079365532 @default.
• W2734929604 cites W2086286894 @default.
• W2734929604 cites W2092347914 @default.
• W2734929604 cites W2096545386 @default.
• W2734929604 cites W2101648653 @default.
• W2734929604 cites W2109205360 @default.
• W2734929604 cites W2115731038 @default.
• W2734929604 cites W2133113022 @default.
• W2734929604 cites W2133201432 @default.
• W2734929604 cites W2135321054 @default.
• W2734929604 cites W2150029176 @default.
• W2734929604 cites W2154643481 @default.
• W2734929604 cites W2166126901 @default.
• W2734929604 cites W2169578616 @default.
• W2734929604 cites W2340007672 @default.
• W2734929604 cites W2565288421 @default.
• W2734929604 cites W2566546873 @default.
• W2734929604 cites W2602518840 @default.
• W2734929604 cites W2720123248 @default.
• W2734929604 cites W4249178543 @default.
• W2734929604 doi "https://doi.org/10.1016/s2352-3026(17)30106-0" @default.
• W2734929604 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28712941" @default.
• W2734929604 hasPublicationYear "2017" @default.
• W2734929604 type Work @default.
• W2734929604 sameAs 2734929604 @default.
• W2734929604 citedByCount "66" @default.
• W2734929604 countsByYear W27349296042017 @default.
• W2734929604 countsByYear W27349296042018 @default.
• W2734929604 countsByYear W27349296042019 @default.
• W2734929604 countsByYear W27349296042020 @default.
• W2734929604 countsByYear W27349296042021 @default.
• W2734929604 countsByYear W27349296042022 @default.
• W2734929604 countsByYear W27349296042023 @default.
• W2734929604 crossrefType "journal-article" @default.
• W2734929604 hasAuthorship W2734929604A5003727895 @default.
• W2734929604 hasAuthorship W2734929604A5003883532 @default.
• W2734929604 hasAuthorship W2734929604A5015424908 @default.
• W2734929604 hasAuthorship W2734929604A5017916035 @default.
• W2734929604 hasAuthorship W2734929604A5021098298 @default.
• W2734929604 hasAuthorship W2734929604A5027127504 @default.
• W2734929604 hasAuthorship W2734929604A5033728782 @default.
• W2734929604 hasAuthorship W2734929604A5042926407 @default.
• W2734929604 hasAuthorship W2734929604A5043670888 @default.
• W2734929604 hasAuthorship W2734929604A5046659441 @default.
• W2734929604 hasAuthorship W2734929604A5049279419 @default.
• W2734929604 hasAuthorship W2734929604A5059428070 @default.
• W2734929604 hasAuthorship W2734929604A5060558357 @default.
• W2734929604 hasAuthorship W2734929604A5065418651 @default.
• W2734929604 hasAuthorship W2734929604A5076337256 @default.
• W2734929604 hasAuthorship W2734929604A5087764727 @default.
• W2734929604 hasConcept C111113717 @default.
• W2734929604 hasConcept C112705442 @default.
• W2734929604 hasConcept C126322002 @default.
• W2734929604 hasConcept C141071460 @default.
• W2734929604 hasConcept C143998085 @default.
• W2734929604 hasConcept C197934379 @default.
• W2734929604 hasConcept C203092338 @default.
• W2734929604 hasConcept C2777058707 @default.
• W2734929604 hasConcept C2778375690 @default.
• W2734929604 hasConcept C2778476033 @default.
• W2734929604 hasConcept C2779338263 @default.
• W2734929604 hasConcept C2780653079 @default.
• W2734929604 hasConcept C535046627 @default.
• W2734929604 hasConcept C61943457 @default.
• W2734929604 hasConcept C71924100 @default.
• W2734929604 hasConcept C73751289 @default.
• W2734929604 hasConceptScore W2734929604C111113717 @default.
• W2734929604 hasConceptScore W2734929604C112705442 @default.
• W2734929604 hasConceptScore W2734929604C126322002 @default.
• W2734929604 hasConceptScore W2734929604C141071460 @default.
• W2734929604 hasConceptScore W2734929604C143998085 @default.
• W2734929604 hasConceptScore W2734929604C197934379 @default.
• W2734929604 hasConceptScore W2734929604C203092338 @default.
• W2734929604 hasConceptScore W2734929604C2777058707 @default.

• next